VALNEVA (EPA:VLA) | Finanzwire

BRIEF

published on 08/20/2024 at 16:06, 1 year 7 months ago

First Berlin Equity Research Reiterates Buy Rating for Valneva SE

Valneva Equity Research Market Undervaluation H1 Results Lyme Vaccine
PRESS RELEASE

published on 08/20/2024 at 16:01, 1 year 7 months ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates research on Valneva SE (ISIN: FR0004056851) with a BUY recommendation and EUR 8.60 price target. H1 product sales slightly below consensus but gross margin improving. Valneva maintains full-year guidance

First Berlin Equity Research Buy Recommendation Valneva SE EUR 8.60 Price Target H1 Product Sales
BRIEF

published on 08/13/2024 at 07:05, 1 year 7 months ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

Financial Results Cash Position Revenue Guidance Valneva Vaccine Development
PRESS RELEASE

published on 08/13/2024 at 07:00, 1 year 7 months ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
Valneva reports first-half 2024 financial results as total revenues reach €70.8 million with net profit of €34.0 million. Company confirms full-year guidance and updates strategic pipeline expansion

Revenues Financial Results Net Profit Valneva Strategic Pipeline
BRIEF

published on 08/06/2024 at 08:35, 1 year 7 months ago

Valneva Announces Share and Voting Right Changes as of July 31, 2024

Euronext Paris Voting Rights Shares Biopharmaceutical Valneva
PRESS RELEASE

published on 08/06/2024 at 08:30, 1 year 7 months ago

VALNEVA - Declaration of shares and voting rights: July 31, 2024
VALNEVA declared changes in shares and voting rights including sale, transfer, and granting of double voting rights on various dates

Voting Rights Shares Sale Transfer Valneva
BRIEF

published on 07/17/2024 at 22:05, 1 year 8 months ago

VALOR Phase 3 Trial: Valneva and Pfizer Finalize Primary Lyme Disease Vaccination

Clinical Test Valneva Pfizer VLA15 Lyme
PRESS RELEASE

published on 07/17/2024 at 22:00, 1 year 8 months ago

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
Phase 3 VALOR Lyme Disease Trial: Pfizer and Valneva announce completion of primary vaccination series with VLA15, progressing towards a Lyme disease vaccine

Valneva Lyme Disease Vaccine Pfizer VLA15 VALOR
BRIEF

published on 06/05/2024 at 07:05, 1 year 9 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Executive Changes Corporate Update Valneva Shareholder Meeting
PRESS RELEASE

published on 06/05/2024 at 07:00, 1 year 9 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Valneva announces availability of documentation for its Combined Shareholder Meeting on June 26, 2024, along with corporate update including change in General Counsel & Corporate Secretary. Kendra Wergin appointed as successor

Corporate Update Valneva General Counsel Shareholder Meeting Kendra Wergin

Published on 03/26/2026 at 04:55, 51 minutes ago

Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives
Published on 03/26/2026 at 00:40, 5 hours 6 minutes ago

Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 5 hours 16 minutes ago

Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 10 hours 31 minutes ago

Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 16 hours 16 minutes ago

Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada

View all ACCESSWIRE

Published on 03/26/2026 at 04:45, 1 hour 1 minute ago

Powering global maritime decarbonization, Shanghai Electric delivers first large-scale biomethanol bunkering for international shipping
Published on 03/26/2026 at 01:05, 4 hours 41 minutes ago

Blokees Announces Upgrade Brand Mission at 2026 Global Partner Conference
Published on 03/25/2026 at 20:00, 9 hours 46 minutes ago

Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Published on 03/25/2026 at 19:41, 10 hours 5 minutes ago

EQS-Adhoc: STRATEC POSTS IMPAIRMENTS, REPORTS PRELIMINARY RESULTS FOR 2025, AND OFFERS GUIDANCE FOR 2026
Published on 03/25/2026 at 19:30, 10 hours 16 minutes ago

AIXTRON to expand global footprint with new plant in Malaysia

View all EQS

Published on 03/25/2026 at 18:53, 10 hours 53 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 11 hours 15 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 12 hours 1 minute ago

Combined General Meeting on May 05, 2026: publication of the notice of Meeting
Published on 03/25/2026 at 17:45, 12 hours 1 minute ago

GUILLEMOT CORPORATION: 2025 ANNUAL RESULTS
Published on 03/25/2026 at 17:42, 12 hours 4 minutes ago

2025/2026 Second quarter Sales

View all LES ECHOS COMFI WIRE

News